The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at $367m (272 million pounds) over five years due to Washington's request for confidential data.
This rejection was revealed following a official document dated December was leaked, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesperson has since stated that the US was requesting biological samples for scientific study and profit but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more talks to secure a agreement acceptable to both sides so the country's critical HIV treatment initiative can continue.
Broader Background
This development follows a similar situation in neighbouring Kenya, where a high court halted a related health funding agreement following concerns were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and responsibility.
Based on statements, 16 nations in Africa have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data for a long time, without any equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research with no assurance that the end products would be available to our citizens should a future disease outbreak emerge."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This framework is designed to guarantee that when a country contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our US partners on how future co-operation might be designed in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts stated it understood the government's concerns, but urged that negotiations must proceed since a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where technical issues exist, such as those involving information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The situation highlights the continuing debate between receiving vital international aid and protecting local interests in an increasingly data-driven world.